Umberto Capitanio1, Carlo Terrone2, Alessandro Antonelli3, Andrea Minervini4, Alessandro Volpe2, Maria Furlan3, Rayan Matloob5, Federica Regis2, Cristian Fiori6, Francesco Porpiglia6, Ettore Di Trapani5, Monica Zacchero2, Sergio Serni4, Andrea Salonia5, Marco Carini4, Claudio Simeone3, Francesco Montorsi5, Roberto Bertini5. 1. Department of Urology, San Raffaele Scientific Institute, Milan, Italy; Division of Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: umbertocapitanio@gmail.com. 2. Department of Urology, University of Piemonte Orientale, Novara, Italy. 3. Department of Urology, Università degli studi e Spedali Civili di Brescia, Brescia, Italy. 4. Department of Urology, Clinica Urologica I, Azienda Ospedaliera Universitaria Careggi, Università degli studi di Firenze, Florence, Italy. 5. Department of Urology, San Raffaele Scientific Institute, Milan, Italy; Division of Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy. 6. Department of Urology, AOU San Luigi Gonzaga, Università degli studi di Torino, Orbassano, Italy.
Abstract
BACKGROUND: Some reports have suggested that nephron-sparing surgery (NSS) may protect against cardiovascular events (CVe) when compared with radical nephrectomy (RN). However, previous studies did not adjust the results for potential selection bias secondary to baseline cardiovascular risk. OBJECTIVE: To test the effect of treatment type (NSS vs RN) on the risk of developing CVe after accounting for individual cardiovascular risk. DESIGN, SETTING, AND PARTICIPANTS: A multi-institutional collaboration including 1331 patients with a clinical T1a-T1b N0 M0 renal mass and normal renal function before surgery (defined as an estimated glomerular filtration rate≥60 ml/min/1.73 m2). INTERVENTION: RN (n=462, 34.7%) or NSS (n=869, 65.3%) between 1987 and 2013. OUTCOME MEASUREMENT AND STATISTICAL ANALYSES: CVe was defined as onset during the follow-up period of coronary artery disease, cardiomyopathy, hypertension, vasculopathy, heart failure, dysrhythmias, or cerebrovascular disease not known before surgery. Cox regression analyses were performed. To adjust for inherent baseline differences among patients, we performed multivariate analyses adjusting for all available characteristics depicting the overall and cardiovascular-specific profile of the patients. RESULTS AND LIMITATIONS: When stratifying for treatment type, the proportion of patients who experienced CVe at 1, 5, and 10 yr was 5.5%, 9.9%, and 20.2% for NSS patients compared to 8.7%, 15.6%, and 25.9%, respectively, for RN patients (p=0.001). In multivariate analyses, patients who underwent NSS showed a significantly lower risk of developing CVe compared with their RN counterparts (hazard ratio 0.57, 95% confidence interval 0.34-0.96; p=0.03) after accounting for clinical characteristics and cardiovascular profile. Limitations include the retrospective design of the study because other potential confounders may exist. CONCLUSIONS: The risk of CVe after renal surgery is not negligible. Patients treated with NSS have roughly half the risk of developing CVe relative to their RN counterparts. After accounting for clinical characteristics, comorbidities, and cardiovascular risk at diagnosis, NSS independently decreases the risk of CVe relative to RN. PATIENT SUMMARY: The risk of having a cardiovascular event after renal surgery decreases if a portion of the affected kidney is spared.
BACKGROUND: Some reports have suggested that nephron-sparing surgery (NSS) may protect against cardiovascular events (CVe) when compared with radical nephrectomy (RN). However, previous studies did not adjust the results for potential selection bias secondary to baseline cardiovascular risk. OBJECTIVE: To test the effect of treatment type (NSS vs RN) on the risk of developing CVe after accounting for individual cardiovascular risk. DESIGN, SETTING, AND PARTICIPANTS: A multi-institutional collaboration including 1331 patients with a clinical T1a-T1b N0 M0 renal mass and normal renal function before surgery (defined as an estimated glomerular filtration rate≥60 ml/min/1.73 m2). INTERVENTION: RN (n=462, 34.7%) or NSS (n=869, 65.3%) between 1987 and 2013. OUTCOME MEASUREMENT AND STATISTICAL ANALYSES: CVe was defined as onset during the follow-up period of coronary artery disease, cardiomyopathy, hypertension, vasculopathy, heart failure, dysrhythmias, or cerebrovascular disease not known before surgery. Cox regression analyses were performed. To adjust for inherent baseline differences among patients, we performed multivariate analyses adjusting for all available characteristics depicting the overall and cardiovascular-specific profile of the patients. RESULTS AND LIMITATIONS: When stratifying for treatment type, the proportion of patients who experienced CVe at 1, 5, and 10 yr was 5.5%, 9.9%, and 20.2% for NSSpatients compared to 8.7%, 15.6%, and 25.9%, respectively, for RN patients (p=0.001). In multivariate analyses, patients who underwent NSS showed a significantly lower risk of developing CVe compared with their RN counterparts (hazard ratio 0.57, 95% confidence interval 0.34-0.96; p=0.03) after accounting for clinical characteristics and cardiovascular profile. Limitations include the retrospective design of the study because other potential confounders may exist. CONCLUSIONS: The risk of CVe after renal surgery is not negligible. Patients treated with NSS have roughly half the risk of developing CVe relative to their RN counterparts. After accounting for clinical characteristics, comorbidities, and cardiovascular risk at diagnosis, NSS independently decreases the risk of CVe relative to RN. PATIENT SUMMARY: The risk of having a cardiovascular event after renal surgery decreases if a portion of the affected kidney is spared.
Authors: Maria C Mir; Nicola Pavan; Umberto Capitanio; Alessandro Antonelli; Ithaar Derweesh; Oscar Rodriguez-Faba; Estefania Linares; Toshio Takagi; Koon H Rha; Christian Fiori; Tobias Maurer; Chao Zang; Alexandre Mottrie; Paolo Umari; Jean-Alexandre Long; Gaelle Fiard; Cosimo De Nunzio; Andrea Tubaro; Andrew T Tracey; Matteo Ferro; Ottavio De Cobelli; Salvatore Micali; Luigi Bevilacqua; João Torres; Luigi Schips; Roberto Castellucci; Ryan Dobbs; Giuseppe Quarto; Pierluigi Bove; Antonio Celia; Bernardino De Concilio; Carlo Trombetta; Tommaso Silvestri; Alessandro Larcher; Francesco Montorsi; Carlotta Palumbo; Maria Furlan; Ahmet Bindayi; Zachary Hamilton; Alberto Breda; Joan Palou; Alfredo Aguilera; Kazunari Tanabe; Ali Raheem; Thomas Amiel; Bo Yang; Estevão Lima; Simone Crivellaro; Sisto Perdona; Caterina Gregorio; Giulia Barbati; Francesco Porpiglia; Riccardo Autorino Journal: World J Urol Date: 2019-04-01 Impact factor: 4.226
Authors: Zachary A Hamilton; Robert G Uzzo; Alessandro Larcher; Brian R Lane; Benjamin Ristau; Umberto Capitanio; Stephen Ryan; Sumi Dey; Andres Correa; Madhumitha Reddy; James A Proudfoot; Ryan Nasseri; Kendrick Yim; Sabrina Noyes; Ahmet Bindayi; Francesco Montorsi; Ithaar H Derweesh Journal: World J Urol Date: 2018-03-12 Impact factor: 4.226
Authors: Frank Kunath; Stefanie Schmidt; Laura-Maria Krabbe; Arkadiusz Miernik; Philipp Dahm; Anne Cleves; Mario Walther; Nils Kroeger Journal: Cochrane Database Syst Rev Date: 2017-05-09
Authors: Julie Y An; Mark W Ball; Michael A Gorin; Jiwon J Hong; Michael H Johnson; Christian P Pavlovich; Mohamad E Allaf; Phillip M Pierorazio Journal: Urology Date: 2016-11-23 Impact factor: 2.649
Authors: Anand Mohapatra; Seth A Strope; Nick Liu; Andrew Winer; Nicole E Benfante; Jonathan A Coleman; Joel Vetter; Katie S Murray Journal: Int Urol Nephrol Date: 2020-03-11 Impact factor: 2.370